Rigel Pharmaceuticals came into this print with a stock that had already run hard over the past three months, then added another 4.6% to close at US$40.48 after the Q2 release. That jump sits on a simple headline. The company stayed profitable and lifted Q2 total revenue to US$78.7m while keeping net income at US$17.3m, even as cash slipped to US$95.3m. For a biotech that trades on promise as much as on product, this quarter was about proving the earnings are real enough to matter.

Is Rigel Pharmaceuticals now a genuine bargain at a 2.3x P/E, or are those large non cash earnings and projected declines doing most of the heavy lifting in the story? Compare the current share price with the implied fair value using the valuation analysis for Rigel Pharmaceuticals

Q2 2026 Earnings Summary

• Total Revenue (Q2 2026 vs. Q2 2025): US$78.7m vs. US$101.7m (revenue declined 22.6%)
• Net Income Excluding Extra Items (Q2 2026 vs. Q2 2025): US$17.3m vs. US$59.6m (net income declined 71.0%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.93 vs. US$3.33 (EPS declined 72.1%)
• Pipeline Breadth (Q2 2026 vs. Q2 2025): Products in Phase I 1 vs. 1 and Products in Phase II 1 vs. 1 (clinical stage count unchanged)

If you prefer clear charts to extensive earnings tables and footnotes, you can view Rigel Pharmaceuticals' full financial picture in a visual breakdown of its valuation in the company report for Rigel Pharmaceuticals.

Rigel Bull Case Hinges On Execution Milestones Met

The bullish story on Rigel Pharmaceuticals is that it can grow into a diversified, profitable oncology and hematology platform by layering in licensed assets on top of a lean commercial base. Q2 results offer some proof points. Product sales of US$67.0m were driven by all three existing drugs, with TAVALISSE and REZLIDHIA each posting double digit year on year growth and GAVRETO still contributing. That supports the idea that the legacy portfolio can fund new launches rather than relying on equity or debt.

The thesis also calls for operating leverage from partner economics. Q2 collaboration revenue of US$11.7m tied to olutasidenib and other partners shows those contracts are delivering cash, not just headlines. Finally, Rigel held Q2 net income at US$17.3m and raised full year revenue guidance while absorbing VEPPANU launch costs, which is an early check mark for the profitability and financial discipline narrative.

Compare this operational progress with how institutions are setting their targets and pricing in the Q2 reaction. See the consensus price target analysis for Rigel Pharmaceuticals

Rigel Bear Case Focuses On Quality Of Earnings

The core bearish worry on Rigel Pharmaceuticals is that recent profitability relies too heavily on narrow products and one-time or noncash items, so earnings may not hold up as growth spending rises. Q2 does not fully clear that hurdle. Product sales are concentrated, with TAVALISSE, REZLIDHIA and GAVRETO still carrying the load while VEPPANU has yet to contribute. Collaboration revenue of US$11.7m again leans on milestones, which fits the concern that a meaningful slice of reported revenue is episodic rather than recurring.

Bears also flag future capital commitments around VEPPANU and R289. Cash fell to US$95.3m by quarter end after the licensing outflows, while Rigel still plans up to US$40m of additional VEPPANU development spend and remains on the hook for sizable milestones. Guidance for full-year profitability helps, but the print does not yet show that core product cash flow comfortably covers these higher commitments without ongoing deal-driven top ups.

After a quarter where Rigel Pharmaceuticals relied on concentrated products, milestone cash and non cash items, it may be worth asking if this is just surface level strength or a sign of deeper fragility. Review our independent risk analysis for Rigel Pharmaceuticals which shows 2 important warning signs

Stay Ahead Of Your Next Move

If Rigel Pharmaceuticals' mix of profitability, milestone income and new product commitments has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis evolves. After you take a position, keep your focus on the numbers that matter most by using the Portfolio Command Center to cut through noise and surface key developments. For a broader view, use the Community to see how other investors are interpreting the same data and what they are watching next. Spotting hidden catalysts and risks early can help you react faster and stay a step ahead of the market.

Seeking Alternatives Beyond Rigel Pharmaceuticals?

Fresh ideas can move fast. Some stocks are building quiet breakout momentum while they are still under the radar for now. Check them before the crowd moves and consider them early.

• Assess sturdier opportunities and stress test your next move against a curated list of solid balance sheet and fundamentals stocks (50 results) so you are not caught holding fragile balance sheets when sentiment drops.
• Review curated 8 dividend fortresses that could help keep cash flowing into your account while prices are still adjusting and yields remain compelling for first movers.
• Scan 17 high quality undiscovered gems early so you are positioned while valuations still reflect early stage curiosity rather than full expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.